Company intelligence / Profile preview

Amber

San Francisco, California, United Statesamber.bio ↗

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Amber Bio is a biotechnology company developing a first-of-its-kind RNA editing platform to treat a broad range of genetic diseases. The company's technology utilizes a novel CRISPR-based system that enables multi-kilobase RNA editing, allowing for the correction of diverse mutations across different patients with a single drug candidate. By targeting RNA rather than DNA, Amber Bio aims to provide a safer and more reversible approach to genetic medicine. The company is currently focused on advancing its platform and identifying lead programs in areas with high unmet medical needs.

Modalities: Gene therapyRNA therapyCRISPR-based therapy
Industry: Biotech

Beyond the preview

Go deeper on Amber.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amber.

Explore the full profile